Abbott's CardioMEMS HF System Scores FDA Nod For Earlier-Stage Heart Failure

Loading...
Loading...

The FDA has approved an expanded indication for Abbott Laboratories' ABT CardioMEMS HF System. 

  • The CardioMEMS HF System was initially approved in 2014 for use in New York Heart Association (NYHA) Class III heart failure patients with a prior heart failure hospitalization within the last year. 
  • The new indication allows the CardioMEMS sensor to be used by people living with Class II heart failure and for patients who undergo a blood test showing elevated biomarkers (natriuretic peptides), which indicate worsening heart failure.
  • The sensor provides an early warning system enabling doctors to protect against worsening heart failure.
  • Also See: Abbott Recalls Baby Formula Manufactured At Michigan Facility.
  • The CardioMEMS sensor is a paperclip-sized device that monitors for pressure changes that indicate worsening heart failure once placed in the pulmonary artery.
  • GUIDE-HF trial data supported the CardioMEMS HF System's expanded indication. 
  • Both Class II heart failure patients and patients with elevated natriuretic peptides were suggested to have better outcomes when their therapy was guided by pulmonary pressure monitoring, with a respective 34% and 25% reduction in heart failure hospitalizations, emergency visits, and death.
  • Class II heart failure is generally categorized as mild heart failure where patients have a slight limitation with physical activity. 
  • Price Action: ABT shares closed 0.63% lower at $116.05 during after-hours trading on Friday.
Loading...
Loading...
Posted In: NewsHealth CareFDAGeneralBriefs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...